| Date | Title | Description |
| 19.09.2024 | Innovent Biologics: Pioneering New Frontiers in Cancer Treatment | In the world of oncology, the quest for effective treatments is relentless. Innovent Biologics, a biopharmaceutical company based in China, is at the forefront of this battle. Recently, they presented groundbreaking clinical data at the 202... |
| 18.09.2024 | Innovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors at the 202... | SAN FRANCISCO and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 18.09.2024 | Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress | SAN FRANCISCO and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 14.09.2024 | Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation | ROCKVILLE, Md. and SUZHOU, China, Sept. 14, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily... |
| 14.09.2024 | SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024 | Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy
BOSTON and ROLLE, Switzerland, Sept. 14, 2024 /PRNewswire/ -- SOP... |
| 12.09.2024 | Head-to-head Superiority over Dulaglutide: Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024 | SAN FRANCISCO and SUZHOU, China, Sept. 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatme... |
| 11.09.2024 | Pioneering Cancer Treatments Take Center Stage at ESMO 2024 | The European Society of Medical Oncology (ESMO) Congress 2024 is set to be a pivotal event in the world of oncology. From September 13 to 17, Barcelona will host a gathering of minds, all focused on the latest breakthroughs in cancer treatm... |
| 11.09.2024 | Innovent Delivers Oral Presentation on Phase 1 Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer at the 2024 WCLC | SAN FRANCISCO and SUZHOU, China, Sept. 11, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 10.09.2024 | Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 Study of Dupert® (Fulzerasib) in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation | SAN FRANCISCO and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 09.09.2024 | ESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO Congress | ROCKVILLE, Md. and SUZHOU, China, Sept. 9, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for malign... |
| 09.09.2024 | Breakthrough Therapy BAY 2927088 Demonstrates 'Rapid, Substantial and Durable Responses' in Patients with HER2-Mutant NSCLC | Xiuning Le, M.D., Ph.D., The University of Texas MD Anderson Cancer Center, Houston
Treatment with BAY 2927088 led to rapid, substantial, and durable responses in patients with heavily pretreated HER2-mutant non-small cell lung cancer (NSCL... |
| 08.09.2024 | Perioperative Nivolumab May Provide Meaningful Improvement in Event-Free Survival Compared to only Neoadjuvant Nivolumab Plus Chemotherapy for Resectable NSCLC | Dr. Patrick Forde of The Bloomberg-Kimmel Institute for Cancer Immunotherapy, The Sidney Kimmel Comprehensive Cancer
New data from landmark analysis presented today report a decreased risk of disease recurrence or death in patients with res... |
| 08.09.2024 | NeoCOAST-2 Data Shows Combination of Durvalumab with novel agents increases pathological responses in resectable NSCLC -- Data Builds on AEGEAN Study Research | Dr. Tina Cascone, from The University of Texas MD Anderson Cancer Center in Houston.
Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete response ... |
| 04.09.2024 | Bridging Cultures and Consciousness: A Look at Spiritual Enlightenment and Cultural Exchange | In a world that often feels divided, two events recently emerged as beacons of hope and connection. One is a meditation course aimed at spiritual enlightenment, while the other is a cultural festival celebrating the rich heritage of Guizhou... |
| 03.09.2024 | The "10 Warning Signs of Spiritual Enlightenment" Will Be Revealed to attendees of the New AMI Meditation Foundation Course Beginning Sunday, September 15, 2024 | Leonard Perlmutter (Ram Lev) American Meditation Institute Founder
Yoga Scientist and originator of National Conscience Month [Leonard Perlmutter] (Ram Lev) will reveal and explain his "10 Warning Signs of Spiritual Enlightenment"... |
| 02.09.2024 | Innovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024 | SAN FRANCISCO and SUZHOU, China, Sept. 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 30.08.2024 | The Intersection of Mindfulness and Modern Medicine: A New Course for Enlightenment | In a world buzzing with distractions, the quest for inner peace often feels like chasing shadows. Yet, a new course promises to illuminate the path to enlightenment. The American Meditation Institute (AMI) is set to launch its "AMI Med... |
| 29.08.2024 | Innovent and Lilly: Pioneering Paths in Biopharmaceuticals | In the ever-evolving landscape of biopharmaceuticals, two companies stand out: Innovent Biologics and Eli Lilly. Both are making waves, each with a unique approach to tackling pressing health issues. Innovent, based in Suzhou, China, is car... |
| 29.08.2024 | Innovent to Present Clinical Data of Multiple Novel Molecules at WCLC and ESMO 2024 | SAN FRANCISCO and SUZHOU, China, Aug. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for ... |
| 28.08.2024 | New Foundation Course for Enlightenment Presented by Leonard Perlmutter (Ram Lev) Begins Sunday, September 15, 2024 | American Meditation Institute
Leonard Perlmutter (Ram Lev) American Meditation Institute Founder
A new six-week "AMI Meditation® Foundation Course for Enlightenment" will be taught by philosopher and Yoga Scientist Leonard Perlmut... |
| 28.08.2024 | Innovent Announces 2024 Interim Results and Business Updates | Strong commercial performance and significant pipeline milestones
support sustained growth and innovation
SAN FRANSISCO and SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopha... |
| 23.08.2024 | Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization | SHANGHAI and HONG KONG, Aug. 23, 2024 /PRNewswire/ -- Antengene Corporation (6996.HK) today announced its interim results for the period ending June 30, 2024, along with several significant milestones achieved in recent months.
Dr. Jay Mei,... |
| 22.08.2024 | China's First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China | SAN FRANCISCO and SUZHOU, China, Aug. 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for ... |
| 20.08.2024 | The Battle for Truth: Navigating the Landscape of Cancer Research and Disinformation | In the realm of cancer research, hope is a beacon. The Society for Immunotherapy of Cancer (SITC) shines that light brightly. Their recent announcement of fellowship recipients is a testament to the commitment to innovation and progress. Wi... |
| 19.08.2024 | Society for Immunotherapy of Cancer Forward Fund Announces Recipients of Cancer Immunotherapy Fellowships | SITC Logo
In its mission to make "cure" a reality for cancer patients everywhere and support the development of early career investigators, the Society for Immunotherapy of Cancer (SITC) Forward Fund is pleased to announce the rec... |
| 13.08.2024 | The Intersection of Jazz and Innovation: Rahsaan Barber and Invenio Imaging Lead the Charge | In the world of music and medicine, two names are making waves: Rahsaan Barber and Invenio Imaging. Each is carving a path in their respective fields, driven by creativity and innovation. Barber, a saxophonist, is breathing new life into ja... |
| 13.08.2024 | Registrational Phase III Study of Lisaftoclax in Newly-Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome Cleared by China CDE | ROCKVILLE, Md. and SUZHOU, China, Aug. 13, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for ma... |
| 09.08.2024 | Invenio Imaging Announces First Patients Enrolled in US Pivotal Study of AI-Based Image Analysis Module for Lung Cancer | SANTA CLARA, Calif., Aug. 9, 2024 /PRNewswire/ -- Invenio Imaging, a leader in intraoperative fresh tissue imaging and artificial intelligence (AI), announced today the enrollment of the first patients in a US pivotal study of its AI-based ... |
| 08.08.2024 | Innovative Anti-Nausea Smartwatch EmeTerm® Smart Set to Launch on Indiegogo | VANCOUVER, BC, Aug. 8, 2024 /PRNewswire/ -- EmeTerm® Smart uses patented hybrid technology to seamlessly integrate the functionality of a smartwatch with that of an anti-nausea wristband, ensuring a carefree and healthy life for all. EmeTer... |
| 08.08.2024 | Innovative Anti-Nausea Smartwatch EmeTerm® Smart Set to Launch on Indiegogo | VANCOUVER, BC, Aug. 8, 2024 /PRNewswire/ -- EmeTerm® Smart uses patented hybrid technology to seamlessly integrate the functionality of a smartwatch with that of an anti-nausea wristband, ensuring a carefree and healthy life for all. EmeTer... |
| 06.08.2024 | Memorial Cancer Institute Welcomes New Chief of Breast Cancer Services Natasha M. Rueth, MD, MS, FACS | Natasha Rueth, MD.
Memorial Healthcare System is proud to announce the addition of Natasha Rueth, MD, MS, FACS, as chief of breast cancer services at Memorial Cancer Institute.
HOLLYWOOD, Fla., Aug. 6, 2024 /PRNewswire-PRWeb/ -- Memorial He... |
| 03.08.2024 | Innovent's Dual Approach to Diabetes and Hypertension: A New Era in Treatment | In the bustling world of biopharmaceuticals, Innovent Biologics is making waves. With two significant announcements in August 2024, the company is positioning itself as a key player in the treatment of chronic diseases like type 2 diabetes ... |
| 02.08.2024 | Innovent and SanegeneBio Announce First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA) | SAN FRANSCISO and SUZHOU, China, Aug. 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 01.08.2024 | Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update | – Axatilimab BLA in refractory chronic GVHD is under Priority Review; PDUFA action date of August 28, 2024 –
– Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 –
– Pivotal AUGME... |
| 26.07.2024 | Advancing Dermatological Research: The American Skin Association's 2024 Grants**
** | ** The American Skin Association (ASA) has taken a bold step forward in the fight against skin diseases. On July 22, 2024, the ASA announced its 2024 research grants, a lifeline for scientists dedicated to understanding and treating skin co... |
| 26.07.2024 | BioVaxys and Innovent: Pioneering New Frontiers in Immunotherapy and Diabetes Treatment**
** | ** In the ever-evolving landscape of biopharmaceuticals, two companies are making waves: BioVaxys Technology Corp. and Innovent Biologics. Each is tackling significant health challenges with innovative approaches. BioVaxys is focused on imm... |
| 26.07.2024 | Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development | SAN FRANCISCO and SUZHOU, China, July 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 22.07.2024 | Innovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA | SAN FRANCISCO and SUZHOU, China, July 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 09.07.2024 | ReEngage Therapeutics Announces Research Agreement to Accelerate Development of ACSS2 Inhibitors as Cancer Therapies | ReEngage partners with globally-recognized cancer center to study ACSS2 and its role in acetate metabolism, histone modification and DNA Damage Response HOUSTON, TX, USA, July 9, 2024 /EINPresswire.com/ -- ReEngage Therapeutics, a biotech c... |
| 08.07.2024 | Olverembatinib Approved for Commercialization in Macau China | ROCKVILLE, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for hematological m... |
| 05.07.2024 | Innovent and IASO Bio Enhance Strategic Collaboration in Cell Therapy | SAN FRANCISCO and SUZHOU, China, July 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 04.07.2024 | Ascentage Pharma Received US$100 Million Option Payment from Takeda | ROCKVILLE, Md. and SUZHOU, China, July 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematol... |
| 02.07.2024 | Innovent Announces Oral Presentation at the ESMO Gastrointestinal Cancers Congress 2024 on Latest Clinical Data of Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junctio... | SAN FRANCISCO and SUZHOU, China, July 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 28.06.2024 | Innovent Provides Interpretation and Updates on Clinical Data from Mazdutide GLORY-1 Study and General Biomedicine Pipeline | SAN FRANCISCO and SUZHOU, China, June 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 25.06.2024 | Innovent Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions | SAN FRANCISCO and SUZHOU, China, June 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 21.06.2024 | Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda | ROCKVILLE, Md. and SUZHOU, China, June 21, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced ... |
| 19.06.2024 | Innovent Reports Oncology Pipeline Updates at Investor Meeting | SAN FRANCISCO and SUZHOU, China, June 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 18.06.2024 | Live from EHA 2024 | Ascentage Pharma Releases Updated Data of Lisaftoclax in Patients with R/R MM and AL Amyloidosis Highlighting Marked Improvement in ORR | SUZHOU, China and ROCKVILLE, Md., June 18, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced ... |
| 18.06.2024 | Live from EHA 2024 | Posters Featuring Results from Three Studies of Olverembatinib, Including Encouraging Data from US Study in CML and Ph+ ALL | SUZHOU, China and ROCKVILLE, Md., June 18, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced ... |
| 17.06.2024 | Imfinzi approved in the US for endometrial cancer | Imfinzi approved in the US for endometrial cancer
Mon, Jun 17, 2024 08:00 CET Report this content
17 June 2024
Imfinzi plus chemotherapy approved in the US for
mismatch repair deficient advanced or recurrent endometrial cancer
Approval base... |
| 14.06.2024 | Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the ... | SAN FRANCISCO and SUZHOU, China, June 14, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 11.06.2024 | Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE | SUZHOU, China, and ROCKVILLE, Md., June 11, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced... |
| 05.06.2024 | Live from ASCO 2024 | Oral Report Released Latest Data of Olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3% | SUZHOU, China and ROCKVILLE, Md., June 5, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced t... |
| 05.06.2024 | Live from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM | SUZHOU, China, and ROCKVILLE, Md., June 5, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced ... |
| 04.06.2024 | Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety | SUZHOU, China and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced t... |
| 03.06.2024 | Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer a... | SAN FRANCISCO and SUZHOU, China, June 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 03.06.2024 | Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatme... | SAN FRANCISCO and SUZHOU, China, June 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 02.06.2024 | Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting | SAN FRANCISCO and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 02.06.2024 | Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer | SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| 02.06.2024 | Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting | SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| 02.06.2024 | Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting | SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| 21.05.2024 | Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease | SAN FRANCISCO and SUZHOU, China, May 21, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 20.05.2024 | Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC) | SAN FRANCISCO and SUZHOU, China, May 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 17.05.2024 | Houston health care institutions receive $22M to attract top recruits | Houston’s Baylor College of Medicine has received a total of $12 million in grants from the Cancer Prevention & Research Institute of Texas to attract two prominent researchers.
The two grants, which are $6 million each, are earmarked f... |
| 16.05.2024 | EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress | SUZHOU, China and ROCKVILLE, Md., May 16, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced t... |
| 14.05.2024 | Hospital players enhance focus on cancer care amid a surge in cases | - |
| 09.05.2024 | Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints | SAN FRANCISCO and SUZHOU, China, May 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment ... |
| 08.05.2024 | Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update | – NDA filing for revumenib in R/R KMT2Ar acute leukemia granted Priority Review under RTOR; PDUFA action date set for September 26, 2024 –
– BLA filing for axatilimab in chronic GVHD granted Priority Review; PDUFA action date set for August... |
| 07.05.2024 | Innovent Receives NMPA Breakthrough Therapy Designation for IBI343（Anti-Claudin18.2 ADC）as Monotherapy for Advanced Gastric Cancer | SAN FRANCISCO and SUZHOU, China, May 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for th... |
| 02.05.2024 | Calquence combination improved PFS in 1L MCL | Calquence combination improved PFS in 1L MCL
Thu, May 02, 2024 08:00 CET Report this content
02 May 2024
Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival... |
| 30.04.2024 | Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO) | SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 25.04.2024 | ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST | SUZHOU, China and ROCKVILLE, Md., April 25, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced... |
| 24.04.2024 | What Oracle's HQ move means for Austin | figcaption>span]:font-sans">
Oracle's headquarters decampment has left us wondering if we should feel bad about ourselves.
Why it matters: Austin's reputation as a shiny rocket ship of prosperity has taken a beating lately.
Layof... |
| 24.04.2024 | 2 Houston startups selected by US military for geothermal projects | Two clean energy companies in Houston have been recruited for geothermal projects at U.S. military installations.
Fervo Energy is exploring the potential for a geothermal energy system at Naval Air Station Fallon in Nevada.
Meanwhile, Sage ... |
| 23.04.2024 | Op-Ed: Removing barriers is critical for the future of Houston's health care workforce | Houston houses one of the most renowned medical communities in the world. However, Texas' current health care workforce shortage has severely impacted the city, with large swaths of the Gulf Coast Region deemed medically underserved. Thousa... |
| 19.04.2024 | Houston's health tech wins, startup opens new facility, and more trending innovation news | Editor's note:Let's roundup the top Houston innovation news from the week. Trending Houston tech and startup articles on InnovationMap included NanoTech moving into its new space, two health tech companies with big wins, and more.
Growing H... |
| 19.04.2024 | Houston founders re-routed to create new trucking logistics app sparked by industry need | In a world where ”the customer is always right," two Houston founders have followed that rule right to their next venture.
Breaker19 — a groundbreaking mobile application built in late 2023 to be an efficient oilfield trucking and hots... |
| 18.04.2024 | Houston-area school secures grant to foster STEM innovation, entrepreneurship | Three academics at Sam Houston State University have secured grant funding to support innovation and entrepreneurship at the university across science, technology, engineering, and mathematics.
Kyle Scott, assistant professor of entrepreneu... |
| 17.04.2024 | Houston university lands $2.5M grant to expand STEM scholarship program for underserved communities | Rice University will expand its Rice Emerging Scholars Program (RESP) over the next two years thanks to a recent grant from the National Science Foundation.
The $2.5 million in NSF funding will allow Rice to increase the number of scholars ... |
| 17.04.2024 | Houston mental health tech startup receives industry validation for bioelectronic device | A new tool in the fight against treatment-resistant depression could be on the horizon thanks to a Rice University professor.
Jacob Robinson, a professor of electrical and computer engineering and of bioengineering is also co-founder and CE... |
| 16.04.2024 | Dallas law firm targets Texas innovation hubs with expansion to Houston, Austin | A Dallas-based law firm has announced two new Texas offices in Houston and Austin.
Founded in Dallas in 2003, Wilson Whitaker Rynell has expanded in the Lone Star State, strategically targeting Austin for its tech scene and Houston for its ... |
| 16.04.2024 | How corporations can implement meaningful innovation, according to this Houston expert | I vividly remember, it was a typical Tuesday at Houston Exponential, and I’m sipping maybe my third coffee of the morning when the phone rings.
On the line is yet another hopeful voice from a newly minted innovation group at a "big com... |
| 16.04.2024 | Unique cell therapy developed in Houston doses inaugural patient | Replay, a genome-writing company headquartered in San Diego, has announced that its first patient has been dosed with an engineered T-Cell Receptor Natural Killer (TCR-NK) cell therapy for relapsed or refractory multiple myeloma.
What does ... |
| 16.04.2024 | Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO) | SAN FRANCISCO and SUZHOU, China, April 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 15.04.2024 | 3 Houston innovators to know this week | Editor's note: Every week, I introduce you to three Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a one-on-one chat with an energy leader, ... |
| 12.04.2024 | Greentown Labs reduces roles at Houston, Boston incubators | Greentown Labs has announced a reduction in its staff, which affects both of its locations.
In a letter addressed to the Greentown Labs community, the organization's CEO and President Kevin Knobloch reported that Greentown will be reducing ... |
| 10.04.2024 | Cancer Drugs: Promises vs. Reality | The accelerated approval program by the FDA promises early access to promising cancer drugs, but do these drugs actually deliver on their potential? A recent study reveals that most cancer drugs granted accelerated approval fail to show sig... |
| 09.04.2024 | Houston organization introduces inaugural cancer-fighting cohort of data sciences, experts | The University of Texas MD Anderson Cancer Center is one step closer to ending cancer thanks to its new institute that's focused on data science.
MD Anderson’s goal with the new Institute for Data Science in Oncology (IDSO) is to advance co... |
| 08.04.2024 | Many cancer drugs remain unproven years after FDA's accelerated approval, study finds | The U.S. Food and Drug Administration's accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients' lives?
In a new study, researchers found that ... |
| 08.04.2024 | AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting | ROCKVILLE, Md. and SUZHOU, China, April 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced ... |
| 08.04.2024 | Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting | ROCKVILLE, Md. and SUZHOU, China, April 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 07.04.2024 | Study: Many cancer drugs remain unproven 5 years after approval | ASSOCIATED PRESS / 2020
A sign for the Food and Drug Administration is displayed outside their offices in Silver Spring, Md. According to research published in the Journal of the American Medical Association, most cancer drugs granted accel... |
| 02.04.2024 | Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status | ROCKVILLE, Md. and SUZHOU, China, April 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 26.03.2024 | Starts April 7: A 6 Week Scientific Spiritual Journey to the Center of Consciousness that Transforms Fear & Anger into Limitless, Positive Creative Power | Leonard Perlmutter (Ram Lev) Foundation Course developer and teacher
The trusted guide to countless students seeking the highest spiritual truth, Leonard Perlmutter (Ram Lev), a living link in the world's oldest health and wisdom tradition ... |
| 21.03.2024 | Study Reveals Link Between Dental Bacteria and Treatment-Resistant Colorectal Cancer | Quincy Jon, Tech Times 21 March 2024, 02:03 pm
New research indicates a potential link between a prevalent oral bacteria, commonly found in tooth plaque, and the occurrence of treatment-resistant colorectal cancer.
The study discovered Fuso... |
| 20.03.2024 | Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study | ATN-031 (also known as ATG-031), is the first anti-CD24 antibody to advance to the clinic in oncology in the United States
The Phase I PERFORM trial, ongoing at four major U.S. cancer centers, is evaluating the safety and preliminary effica... |
| 20.03.2024 | Innovent Announces 2023 Annual Results and Business Updates | A transformative year of strong performance and material innovation progress
ROCKVILLE, M.D. and SUZHOU, China, March 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that d... |
| 20.03.2024 | Women are Reshaping the AI Talent Landscape New Research Shows Exponential Global Growth | Zeki Research finds Women prioritize excellence in research, science, and engineering throughout their careers and express greater interest in making AI safe for society through their professional work
LONDON, March 20, 2024 /PRNewswire/ --... |
| 19.03.2024 | Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD) | ROCKVILLIE, Md. and SUZHOU, China, March 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines f... |
| 12.03.2024 | Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting | ROCKVILLE, Md. and SUZHOU, China, March 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines fo... |
